These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3033311)

  • 1. Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.
    Whang Y; Silberklang M; Morgan A; Munshi S; Lenny AB; Ellis RW; Kieff E
    J Virol; 1987 Jun; 61(6):1796-807. PubMed ID: 3033311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells.
    Nuebling CM; Buck M; Boos H; von Deimling A; Mueller-Lantzsch N
    Virology; 1992 Nov; 191(1):443-7. PubMed ID: 1329330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformation-dependent recognition of baculovirus-expressed Epstein-Barr virus gp350 by a panel of monoclonal antibodies.
    Zhang PF; Marcus-Sekura CJ
    J Gen Virol; 1993 Oct; 74 ( Pt 10)():2171-9. PubMed ID: 7691988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
    Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
    Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
    Khyatti M; Patel PC; Stefanescu I; Menezes J
    J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus.
    Schultz LD; Tanner J; Hofmann KJ; Emini EA; Condra JH; Jones RE; Kieff E; Ellis RW
    Gene; 1987; 54(1):113-23. PubMed ID: 3038696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones.
    Khyatti M; Patel PC; Menezes J
    Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
    Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
    Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
    Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
    Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    Thorley-Lawson DA; Poodry CA
    J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge.
    Emini EA; Schleif WA; Silberklang M; Lehman D; Ellis RW
    J Med Virol; 1989 Feb; 27(2):120-3. PubMed ID: 2537882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
    Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
    Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo.
    Servat E; Ro BW; Cayatte C; Gemmell L; Barton C; Rao E; Lin R; Zuo F; Woo JC; Hayes GM
    Vaccine; 2015 Nov; 33(48):6771-7. PubMed ID: 26485517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
    Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
    J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants.
    Zhang PF; Klutch M; Armstrong G; Qualtiere L; Pearson G; Marcus-Sekura CJ
    J Gen Virol; 1991 Nov; 72 ( Pt 11)():2747-55. PubMed ID: 1719128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.
    Tanner J; Whang Y; Sample J; Sears A; Kieff E
    J Virol; 1988 Dec; 62(12):4452-64. PubMed ID: 2460635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen.
    Bugli F; Bastidas R; Burton DR; Williamson RA; Clementi M; Burioni R
    Hum Immunol; 2001 Apr; 62(4):362-7. PubMed ID: 11295468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.